In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, scPharmaceuticals Inc (NASDAQ: SCPH) closed at $3.01 down -0.99% from its previous closing price of $3.04. In other words, the price has decreased by -$0.99 from its previous closing price. On the day, 0.57 million shares were traded. SCPH stock price reached its highest trading level at $3.19 during the session, while it also had its lowest trading level at $2.9.
Ratios:
For a deeper understanding of scPharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.89 and its Current Ratio is at 8.08. In the meantime, Its Debt-to-Equity ratio is 1.71 whereas as Long-Term Debt/Eq ratio is at 1.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on September 07, 2023, initiated with a Buy rating and assigned the stock a target price of $20.
On December 01, 2022, Cowen started tracking the stock assigning a Outperform rating and target price of $25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 13 ’24 when ORBIMED ADVISORS LLC bought 500,000 shares for $4.00 per share. The transaction valued at 2,000,000 led to the insider holds 5,806,670 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SCPH now has a Market Capitalization of 150620704. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.00 while its Price-to-Book (P/B) ratio in mrq is 4.90.
Stock Price History:
The Beta on a monthly basis for SCPH is 0.31, which has changed by -0.41779494 over the last 52 weeks, in comparison to a change of 0.08190584 over the same period for the S&P500. Over the past 52 weeks, SCPH has reached a high of $5.70, while it has fallen to a 52-week low of $2.75. The 50-Day Moving Average of the stock is -8.26%, while the 200-Day Moving Average is calculated to be -25.44%.
Shares Statistics:
For the past three months, SCPH has traded an average of 430.03K shares per day and 651340 over the past ten days. A total of 50.04M shares are outstanding, with a floating share count of 34.09M. Insiders hold about 31.88% of the company’s shares, while institutions hold 65.15% stake in the company. Shares short for SCPH as of 1740700800 were 6283415 with a Short Ratio of 14.61, compared to 1738281600 on 5606224. Therefore, it implies a Short% of Shares Outstanding of 6283415 and a Short% of Float of 14.19.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of scPharmaceuticals Inc (SCPH) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.21 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.7 and -$1.15 for the fiscal current year, implying an average EPS of -$0.92. EPS for the following year is -$0.22, with 4.0 analysts recommending between $0.55 and -$0.65.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $11.63M this quarter.It ranges from a high estimate of $12.5M to a low estimate of $9.04M. As of the current estimate, scPharmaceuticals Inc’s year-ago sales were $6.1MFor the next quarter, 5 analysts are estimating revenue of $16.43M. There is a high estimate of $18M for the next quarter, whereas the lowest estimate is $14.47M.
A total of 6 analysts have provided revenue estimates for SCPH’s current fiscal year. The highest revenue estimate was $85M, while the lowest revenue estimate was $69.7M, resulting in an average revenue estimate of $76.23M. In the same quarter a year ago, actual revenue was $36.33MBased on 6 analysts’ estimates, the company’s revenue will be $135.27M in the next fiscal year. The high estimate is $170M and the low estimate is $111.2M.
